Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | PRSS8 | Q16651 | 1/20 | 0.35 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
| ▸ | TOP2A | P11388 | 1/20 | 0.34 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7049041 | 0.95 | ATM (0.38) | CYP3A4ATMELANENPC1RAB9A | |
| SCHEMBL7575216 | 0.89 | FAAH (0.36) | CYP3A4NPC1RAB9AXDH | |
| SCHEMBL6467033 | 0.89 | FAAH (0.36) | CYP3A4NPC1RAB9AXDH | |
| SCHEMBL7466136 | 0.86 | FAAH (0.36) | CYP3A4XDH | |
| SCHEMBL6466197 | 0.86 | FAAH (0.36) | CYP3A4XDH | |
| SCHEMBL7045498 | 0.82 | PRSS8 (0.49) | CYP3A4ELANEPRSS8XDH | |
| SCHEMBL7049081 | 0.78 | ATM (0.37) | CYP3A4ATMELANETOP2ATOP2B | |
| SCHEMBL7147621 | 0.77 | HDAC3 (0.45) | CYP3A4 | |
| SCHEMBL7046962 | 0.77 | PRSS8 (0.49) | CYP3A4ELANEPRSS8XDH | |
| SCHEMBL6467283 | 0.77 | MEN1 (0.38) | NPC1RAB9AXDHMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | CYP3A4 1183/4885ATM 3419/4885ELANE 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.